<DOC>
	<DOCNO>NCT01831856</DOCNO>
	<brief_summary>The purpose study assess efficacy F373280 maintenance normal cardiac rhythm direct electric cardioversion patient persistent atrial fibrillation cardiac failure .</brief_summary>
	<brief_title>Efficacy Safety Study F373280</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Men woman age 18 year ( inclusive ) Patients current episode persistent AF 7 day 6 month duration electrical cardioversion warrant Previous history first document episode persistent AF . Previous history ischemic non ischemic heart failure NYHA class I II chronic heart failure selection inclusion Left ventricular systolic dysfunction define selection inclusion reduce left ventricular ejection fraction ( LVEF ) ≥ 30 % ≤ 45 % patient LVEF &gt; 45 % : increase leave ventricular enddiastolic size ( diameter ≥ 60 mm and/or &gt; 32 mm/m² and/or volume &gt; 97 ml/m² ) and/or increase leave ventricular endsystolic size ( diameter &gt; 45 mm and/or &gt; 25 mm/m² and/or volume &gt; 43 ml/m² ) and/or reduce leave ventricular outflow tract velocity time integral &lt; 15 cm On appropriate , stable medical treatment heart failure , include diuretic and/or angiotensinconverting enzyme , and/or angiotensinreceptor blocker and/or mineralocorticoid receptor ( MR ) antagonists , and/or betablockers Left atrial area ≤ 40 cm² selection inclusion Patients treat treated vitamin K antagonist For female patient childbearing potential : In country except Italy : Use effective method contraception ( hormonal contraception intrauterine device ) assess investigator , least 2 month selection study , agreement go use whole duration study 1 month last dose study treatment Documented surgically sterilize In Italy : Absolute abstention sexual intercourse whole duration study month end study Use double barrier contraception method ( use effective medical contraception method ) least 2 month start study entire duration study month end study Documented surgically sterilize . For female patient childbearing potential : negative urine pregnancy test inclusion For male childbearing potential partner ( In Italy ) : Absolute abstention sexual intercourse whole duration study 3 month end study Use double barrier contraception method ( use condom male effective contraception method partner ) entire duration study 3 month end study . Ethical / legal consideration : Having sign his/her write informed consent , Affiliated social security system , beneficiary ( applicable national regulation ) No previous history first document episode persistent AF More two successful cardioversions ( electrical pharmacological ) last 6 month Secondary Atrial Fibrillation due alcohol severe valvular heart disease ( grade III IV ) NYHA class III IV heart failure selection inclusion Thyroid disease uncontrolled treatment : TSH ± T4L ± T3L check case treatment thyroid disease Myocardial infarction unstable angina presence unstable ischemic coronaropathy assess coronarography cardiac stress test ( Echo stress , exercise stress test , nuclear MR perfusion evaluation method ) within 6 month selection Severe chronic kidney disease ( creatinine ≥ 25 mg/L estimate glomerular filtration rate &lt; 30 ml/min ) selection Bradycardia ( HR ≤ 50 bpm ) Hyperkalemia hypokalemia ( accord standard local laboratory ) selection Cardiac surgery within 3 month selection plan study duration Criteria related treatment : Previously ineffective pharmacological electrical cardioversion Concomitant treatment ranolazine antiarrhythmic drug ( within 7 day prior selection ) , except amiodarone , dronedarone stable dose digoxin , betablockers , calciumblockers Concomitant treatment oral amiodarone dronedarone selection Concomitant treatment intravenous amiodarone selection Patient require cardiac resynchronization therapy ( CRT ) undergone CRT implantation within last 6 month Treatment Polyunsaturated Fatty Acid ( PUFA ) within last 3 month Dietary supplement ω 3 ω 6 accord investigator 's judgement Having undergone form ablation therapy AF Patient treat oral anticoagulant treatment vitamin K antagonist : new oral anticoagulant ( dabigatran , rivaroxaban , apixaban ) , treat irreversible antiplatelet agent P2Y12 inhibitor ticlopidine , clopidogrel prasugrel Other criterion : Patient liable comply protocol instruction and/or treatment , investigator 's opinion Patient take part clinical trial precede 2 month take part trial time selection Patient linguistically mentally unable understand nature , objectives possible consequence trial , refuse patient himself/herself constraint Patient family member work associate ( secretary , nurse , technician , .. ) Investigator Patient forfeit / freedom administrative legal award guardianship Breastfeeding female patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Chronic Heart Failure</keyword>
</DOC>